CliffBio
small molecule

SODIUM BICARBONATE

SODIUM BICARBONATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameSODIUM BICARBONATE
Active ingredientSODIUM BICARBONATE
Strength2.5MEQ/5ML (0.5MEQ/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2025
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.